Piper sees ‘many catalysts’ to move Motus GI shares higher

Piper Jaffray analyst Matt O’Brien reiterates an Overweight rating on Motus GI Holdings with an $8 price target following the company’s Q4 results and updates ahead of the expected commercialization of Pure-Vu, still set to begin mid-May. The company reported positive interim findings from its Reduce study as well as announced its expectation to file for a Special 510k for the next-gen Pure-Vu product in the coming months, O’Brien tells investors in a research note. There are “many catalysts” ahead to allow shares of Motus GI to move higher, including the May launch, Gen-2 510k clearance, Reduce readout, and initiation of additional studies, adds the analyst. He recommend micro-cap investors take a look at Motus GI Holdings.
https://thefly.com/landingPageNews.php?id=2885163